Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APC(Min)/+ mice

Nature Medicine

Volumn 4, Issue 9, 1998, Pages 1053-1057

  Lefebvre, Anne Marie ^a   Chen, Inhua ^b   Desreumaux, Pierre ^c   Najib, Jamila ^a   Fruchart, Jean Charles ^a   Geboes, Karel ^b   Briggs, Mike ^d   Heyman, Rich ^d   Auwerx, Johan ^a  

^a INSERM   (France)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BETA CATENIN; CYCLOOXYGENASE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ROSIGLITAZONE; TROGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; COLON TUMOR; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG EFFECT; GENE MUTATION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY;

ADENOCARCINOMA; ANIMALS; BETA CATENIN; CHROMANS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYTOSKELETAL PROTEINS; HT29 CELLS; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

ANIMALIA;

EID: 0031694577     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/2036     Document Type: Article

References (38)

1. Kinzler, K.W. & Vogelstein, B. Lessons from heriditary colorectal cancer. Cell 87, 159-170 (1996).
2. Thun, M.J., Namboodiri, M.M. & Heath, C.W. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325, 1593-1596 (1991).
3. Oshima, M. et al. Suppression of intestinal polyposis in APCΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87, 803-809 (1996).
4. Jacoby, R.F. et al. Chemoprevention of spontaneous intestinal adenoma in the ApcMin mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res. 56, 710-714 (1996).
5. Giovanucci, E. & Willet, W.C. Dietary factors and risk of colon cancer. Ann. Med. 26, 443-452 (1994).
6. Wasan, H.S., Novelli, M., Bee, J. & Bodmer, W.F. Dietary fat influences on polyp phenotype in multiple intestinal neoplasia mice. Proc. Natl. Acad. Sci. USA 94, 3308-3313 (1997).
7. Schoonjans, K., Martin, C., Staels, B. & Auwerx, J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol. 8, 159-166 (1997).
8. Fajas, L. et al. Organization, promoter analysis and expression of the human PPARγ gene. J. Biol. Chem. 272, 18779-18789 (1997).
9. Mansen, A., Guardiola-Diaz, H., Rafter, J., Branting, C. & Gustafsson, J.A. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem. Biophys. Res. Commun. 222, 844-851 (1996).
10. Tontonoz, P., Hu, E. & Spiegelman, B.M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79, 1147-1156 (1994).
11. Lehmann, J.M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for Peroxisome Proliferator-Activated Receptor γ (PPARγ). J. Biol. Chem. 270, 12953-12956 (1995).
12. Forman, B.M. et al. 15-Deoxy-Δ12,14 prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83, 803-812 (1995).
13. Kliewer, S.A. et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83, 813-819 (1995).
14. Su, L.K. et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256, 668-670 (1992).
15. Nishisho, I. et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253, 665-669 (1991).
16. Groden, J. et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66, 589-600 (1991).
17. Powell, S.M. et al. Molecular diagnosis of familial adenomatous polyposis. N. Engl. J. Med. 329, 1982-1987 (1993).
18. Miyoshi, Y. et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum. Mol. Genet. 1, 229-233 (1992).
19. Altiok, S., Xu, M. & Spiegelman, B. PPARγ induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 11, 1987-1998 (1997).
20. Shao, D. & Lazar, M.A. Peroxisome proliferator activated receptor γ, CCAAT/enhancer binding protein α, and cell cycle status regulate the commitment to adipocyte differentiation. J. Biol. Chem. 272, 21473-21478 (1997).
21. Tontonoz, P. et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc. Natl. Acad. Sci. USA 94, 237-241 (1997).
22. Hunter, T. Oncoprotein networks. Cell 88, 333-346 (1997).
23. Willert, K. & Nusse, R. β-catenin: a key mediator of Wnt signalling. Curr. Opin. Genet. Develop. 8, 95-102 (1998).
24. Levy, G.D. Prostaglandin H synthethases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB Journal 11, 234-247 (1997).
25. Tsuji, M. & DuBois, R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83, 493-501 (1995).
26. Dietrich, W.F. et al. Genetic identification of Mom-1 a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell 75, 631-639 (1993).
27. Min-induced intestinal neoplasia. Cell 81, 957-966 (1995).
28. Cormier, R.T. et al. Secretory phospholipase PLa2g2a confers resistance to intestinal tumorigenesis. Nature Genet. 17, 88-91 (1997).
29. Charalambous, D. & O'Brien, P.E. Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis. J. Gastroenterol. Hepatol. 11, 307-310 (1996).
30. Piazza, G.A. et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 57, 2909-2915 (1997).
31. Chiu, C.H., McEntee, M.F. & Whelan, J. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin synthesis. Cancer Res. 57, 4267-4273 (1997).
32. Scheppach, W. Effects of short chain fatty acids on gut morphology and function. Gut 35, S35-S38 (1994).
33. Singh, B., Halestrap, A.P. & Paraskeva, C. Butyrate can act as a stimulator growth or inducer of apoptosis in human colonic epithelial cell lines depending on the presence of alternative energy sources. Carcinogenesis 18, 1265-1270 (1997).
34. Holm, E. et al. Substrate balances across colonic carcinomas in humans. Cancer Res. 55, 1373-1378 (1995).
35. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J. & Glass, C.K. The peroxisome proliferator-activated receptor γ is a negative regulator of macrophage activation. Nature 391, 79-82 (1998).
36. Jiang, C., Ting, A.T. & Seed, B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86 (1998).
37. Saez, E. et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nature Med. 4, XXX-XXX (1998).
38. Staels, B. et al. Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal Acyl Co-enzyme A Oxidase. J. Clin. Invest. 95, 705-712 (1995).